Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice
Authors:
Open Access
- 9 June 2014
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 177 (1) , 94-101
Abstract
Summary: SEW2871, a selective sphingosine-1-phosphate type 1 receptor (S1P1) agonist, has been shown to be effective in protecting kidneys against ischaemia–reperfusion injury by reducing CD4+ T cell infiltration in mice. However, the effects of SEW2871 on colitis remain unclear. The aim of this study was to investigate the effects of SEW2871 on established colitis in interleukin (IL)-10 gene-deficient (IL-10–/–) mice, a murine model of Crohn's disease (CD). SEW2871 was administered by gavage at a dose of 20 mg/kg/day for 2 weeks to IL-10–/– mice. Severity of colitis, serum amyloid A, tissue myeloperoxidase (MPO), T cells in blood and colon lamina propria (LP) and proinflammatory cytokine productions were evaluated. Furthermore, the phospho-signal transducer and activator of transcription (STAT)-3 (p-STAT-3) expression in lymphocytes isolated from colon LP was also assessed. The 2-week administration of SEW2871 ameliorated established colitis in IL-10–/– mice, associated with a reduction of serum amyloid A concentration, a decreased colon MPO concentration, a depletion of the peripheral CD4+ CD45+ T cells and a reduction of the homing of T cells into colon LP. Moreover, typical cytokines of T helper type 1 (Th1) and Th17 cells and p-STAT-3 expression were also suppressed by SEW2871 treatment. SEW2871 treatment ameliorates established experimental colitis in IL-10–/– mice, which may provide a new therapeutic approach for human CD therapy.Keywords
Funding Information
- National Ministry of Health for the Digestive Disease (201002020)
- National Natural Science Foundation of China (81200263, 30972881, 81170365)
- Model Animal Research Center, Nanjing University
This publication has 43 references indexed in Scilit:
- Development of small-molecule inhibitors of sphingosine-1-phosphate signalingPharmacology & Therapeutics, 2011
- The outs and the ins of sphingosine-1-phosphate in immunityNature Reviews Immunology, 2011
- Inflammatory Bowel DiseaseAnnual Review of Immunology, 2010
- The alliance of sphingosine-1-phosphate and its receptors in immunityNature Reviews Immunology, 2008
- Therapeutic benefit of pentostatin in severe IL-10−/− ColitisInflammatory Bowel Diseases, 2008
- “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic TargetsPharmacological Reviews, 2008
- IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent MannerJournal of Biological Chemistry, 2007
- Interleukin-2 receptor signaling in regulatory T cell development and homeostasisImmunology Letters, 2007
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.Journal of Clinical Investigation, 1996